Prophylactic Use of Factor VIII: an Economic Evaluation

Rhonda L. Bohn(Brigham and Women's Hospital), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Igor Choodnovskiy, Jerry Avorn(Brigham and Women's Hospital), Rudy H. Haschemeyer, Robert J. Glynn

Thrombosis and Haemostasis

January 1, 1998

10.1055/s-0037-1615097

Cited by 98

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

|The Lancet|2008|862

Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.

|PubMed|2001|803

Definitions in Hemophilia

|Thrombosis and Haemostasis|2001|772

A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs

|Journal of Internal Medicine|1994|613

A More Uniform Measurement of Factor VIII Inhibitors

|Thrombosis and Haemostasis|1975|587